Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor
This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.
Solid Tumor
DRUG: Camrelizumab|DRUG: Famitinib
Response Rate, Response Rate, Up to 18 months
PFS, Progression-free Survival, Up to 18 months|DOR, Duration of Response, Up to 18months|DCR, Disease Control Rate, Up to 18months|TTR, Time to Response, Up to 18 months|OS, overall survival rate, Up to 18 months|The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0, The incidence and severity of adverse events (AEs) and serious adverse events (SAEs) as assessed by CTCAE v5.0 (SAEs) as assessed by CTCAE v5.0, Up to 18 months|Proportion of dose suspension, dose reduction or dose discontinuation caused by treatment-related toxicities., Proportion of dose suspension, dose reduction or dose discontinuation caused by treatment-related toxicities., Up to 18 months|Proportion of anti-camrelizumab antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline, Proportion of anti-camrelizumab antibody (ADA) and neutralizing antibody (Nab) formed during the study from baseline, Up to 18 months|Serum concentration of camrelizumab, Serum concentration of camrelizumab, Up to 18 months|Plasma concentration of famitinib, Plasma concentration of famitinib, Up to 18 months
This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.